企业里程碑 - 智享生物

企业里程碑

这里是标题

Dec.

The first commercial pre-filled syringe PPQ project was successfully completed

Awarded as one of the Top 20 Chinese Pharmaceutical CDMO Enterprises in 2022 in the Great Health Industry
Nov.

Listed in the "Top 100 Chinese Life Science Service Enterprise Brands 2022"

"Top 100 Future Healthcare in 2022·China's Innovative Biomedicine List"
Oct.

Site Ⅲ completed the first batch production of 4x6,000L stainless steel production line

Listed in the "Top 100 Life Sciences in China 2022"
Aug.

Obtained more than 500 million yuan of C round financing, enabling global customers to accelerate the development of biological drugs
Jun.

Intellective Bio has been recognized as a national "high-tech enterprise"

SiteⅡ obtained the "Drug Production License"

Listed in the "2022 Future Medical Top 100 Innovative Biomedicine in China"

Signed commercial orders amounting to more than 90 million yuan
May.

Intellective Bio and Umabs Therapeutics reached a strategic cooperation, AI to help antibody drug development evaluation
Apr.

The fourth anniversary of Intellective Bio
Mar.

Intellective Bio new biological pharmaceutical preparation project signed landing in Changshu High-tech Zone

Intellective Bio drug project signed landing in Taicang
Jan.

Obtained "Biosafety Laboratory Record Certificate" Laboratory level: BSL-2

Selected into the list of potential unicorn enterprises in Jiangsu Province

这里是标题

这里是标题

Dec.

Obtained the Drug Manufacturing License

Obtained hundreds of millions of B round financing

The first commercial order is signed
Nov.

Won the "China Biomedical CDMO Star of Tomorrow" award
Aug.

Completed the first batch of 2,000L GMP production
Jul.

The virus testing laboratory was put into operation
Mar.

The first general contract business received the approval

The production line of 2,000L GMP raw liquid was accepted and put into operation
Feb.

The QC laboratory has been put into use
Jan.

The first cooperative customer got the AU IND approval

Won the "High Quality Development Innovation " award

这里是标题

Dec.

Delivered the first developability assessment and molecular modification project

Meet the GMP production conditions, and obtain the drug production license
Nov.

The first cooperative customer got the CN IND approval
Sept.

Completed the first batch of 500L GMP production

The cumulative order amount is more than 200 million yuan, and 100 employees
Jul.

The project is the development and construction of a biomedical platform based on bispecspecific antibody expression technology
Jun.

Delivered the first business mandate from cell line construction to 3 IND batches
Apr.

Enter the List of Suzhou Maker Spaces 2019 - Intellective Bio Maker
Jan.

The 5,700L GMP workshop was accepted and put into operation

这里是标题

智享生物CEO作为工商领导人代表出席旧金山APEC

2022年江苏省专精特新中小企业